Go Pro
→ From the man who predicted 2008 crash… (From Porter & Company) (Ad)tc pixel Free SOPH Stock Alerts

SOPHiA GENETICS (SOPH) Competitors

SOPHiA GENETICS logo
$5.72 +0.07 (+1.24%)
Closing price 07/13/2026 04:00 PM Eastern
Extended Trading
$5.61 -0.11 (-1.99%)
As of 07/13/2026 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

SOPH vs. MAZE, CMPS, NNNN, TRLV, and VIR

Should you buy SOPHiA GENETICS stock or one of its competitors? MarketBeat compares SOPHiA GENETICS with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SOPHiA GENETICS include Maze Therapeutics (MAZE), Compass Pathways (CMPS), Anbio Biotechnology (NNNN), Trulieve Cannabis (TRLV), and Vir Biotechnology (VIR). These companies are all part of the "pharmaceutical products" industry.

How does SOPHiA GENETICS compare to Maze Therapeutics?

SOPHiA GENETICS (NASDAQ:SOPH) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Maze Therapeutics has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -44.48%. Maze Therapeutics' return on equity of -36.62% beat SOPHiA GENETICS's return on equity.

Company Net Margins Return on Equity Return on Assets
SOPHiA GENETICS-44.48% -62.74% -21.85%
Maze Therapeutics N/A -36.62%-31.78%

SOPHiA GENETICS has higher earnings, but lower revenue than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOPHiA GENETICS$77.27M6.21-$79M-$0.52N/A
Maze Therapeutics$167.50M9.64-$131.12M-$2.53N/A

SOPHiA GENETICS presently has a consensus target price of $7.50, suggesting a potential upside of 31.12%. Maze Therapeutics has a consensus target price of $66.00, suggesting a potential upside of 126.18%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maze Therapeutics is more favorable than SOPHiA GENETICS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SOPHiA GENETICS
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Maze Therapeutics
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.00

In the previous week, SOPHiA GENETICS had 14 more articles in the media than Maze Therapeutics. MarketBeat recorded 17 mentions for SOPHiA GENETICS and 3 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.42 beat SOPHiA GENETICS's score of 0.02 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SOPHiA GENETICS
6 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Maze Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

SOPHiA GENETICS has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market.

31.6% of SOPHiA GENETICS shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by insiders. Comparatively, 5.3% of Maze Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Maze Therapeutics beats SOPHiA GENETICS on 11 of the 17 factors compared between the two stocks.

How does SOPHiA GENETICS compare to Compass Pathways?

SOPHiA GENETICS (NASDAQ:SOPH) and Compass Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Compass Pathways has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -44.48%. Compass Pathways' return on equity of -31.07% beat SOPHiA GENETICS's return on equity.

Company Net Margins Return on Equity Return on Assets
SOPHiA GENETICS-44.48% -62.74% -21.85%
Compass Pathways N/A -31.07%-11.40%

31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by insiders. Comparatively, 2.8% of Compass Pathways shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

SOPHiA GENETICS has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.47, suggesting that its stock price is 147% more volatile than the broader market.

In the previous week, Compass Pathways had 2 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 19 mentions for Compass Pathways and 17 mentions for SOPHiA GENETICS. Compass Pathways' average media sentiment score of 0.29 beat SOPHiA GENETICS's score of 0.02 indicating that Compass Pathways is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SOPHiA GENETICS
6 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Compass Pathways
0 Very Positive mention(s)
5 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

SOPHiA GENETICS has higher revenue and earnings than Compass Pathways. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOPHiA GENETICS$77.27M6.21-$79M-$0.52N/A
Compass PathwaysN/AN/A-$287.86M-$3.15N/A

SOPHiA GENETICS currently has a consensus target price of $7.50, suggesting a potential upside of 31.12%. Compass Pathways has a consensus target price of $24.15, suggesting a potential upside of 83.12%. Given Compass Pathways' stronger consensus rating and higher probable upside, analysts clearly believe Compass Pathways is more favorable than SOPHiA GENETICS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SOPHiA GENETICS
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Compass Pathways
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
1 Strong Buy rating(s)
2.94

Summary

Compass Pathways beats SOPHiA GENETICS on 12 of the 16 factors compared between the two stocks.

How does SOPHiA GENETICS compare to Anbio Biotechnology?

SOPHiA GENETICS (NASDAQ:SOPH) and Anbio Biotechnology (NASDAQ:NNNN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

SOPHiA GENETICS presently has a consensus price target of $7.50, suggesting a potential upside of 31.12%. Given SOPHiA GENETICS's stronger consensus rating and higher probable upside, equities analysts clearly believe SOPHiA GENETICS is more favorable than Anbio Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SOPHiA GENETICS
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Anbio Biotechnology
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

SOPHiA GENETICS has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.15, meaning that its share price is 415% more volatile than the broader market.

Anbio Biotechnology has lower revenue, but higher earnings than SOPHiA GENETICS.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOPHiA GENETICS$77.27M6.21-$79M-$0.52N/A
Anbio Biotechnology$8.65M165.85$6.40MN/AN/A

Anbio Biotechnology has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -44.48%. Anbio Biotechnology's return on equity of 0.00% beat SOPHiA GENETICS's return on equity.

Company Net Margins Return on Equity Return on Assets
SOPHiA GENETICS-44.48% -62.74% -21.85%
Anbio Biotechnology N/A N/A N/A

31.6% of SOPHiA GENETICS shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, SOPHiA GENETICS had 16 more articles in the media than Anbio Biotechnology. MarketBeat recorded 17 mentions for SOPHiA GENETICS and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.87 beat SOPHiA GENETICS's score of 0.02 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company Overall Sentiment
SOPHiA GENETICS Neutral
Anbio Biotechnology Very Positive

Summary

SOPHiA GENETICS and Anbio Biotechnology tied by winning 7 of the 14 factors compared between the two stocks.

How does SOPHiA GENETICS compare to Trulieve Cannabis?

Trulieve Cannabis (NYSE:TRLV) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Trulieve Cannabis has higher revenue and earnings than SOPHiA GENETICS.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trulieve Cannabis$1.17B1.47N/AN/AN/A
SOPHiA GENETICS$77.27M6.21-$79M-$0.52N/A

Trulieve Cannabis has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -44.48%. Trulieve Cannabis' return on equity of 0.00% beat SOPHiA GENETICS's return on equity.

Company Net Margins Return on Equity Return on Assets
Trulieve CannabisN/A N/A N/A
SOPHiA GENETICS -44.48%-62.74%-21.85%

SOPHiA GENETICS has a consensus target price of $7.50, indicating a potential upside of 31.12%. Given SOPHiA GENETICS's stronger consensus rating and higher possible upside, analysts clearly believe SOPHiA GENETICS is more favorable than Trulieve Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trulieve Cannabis
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
SOPHiA GENETICS
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, SOPHiA GENETICS had 10 more articles in the media than Trulieve Cannabis. MarketBeat recorded 17 mentions for SOPHiA GENETICS and 7 mentions for Trulieve Cannabis. Trulieve Cannabis' average media sentiment score of 0.21 beat SOPHiA GENETICS's score of 0.02 indicating that Trulieve Cannabis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Trulieve Cannabis
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
SOPHiA GENETICS
6 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

31.6% of SOPHiA GENETICS shares are held by institutional investors. 3.8% of Trulieve Cannabis shares are held by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

SOPHiA GENETICS beats Trulieve Cannabis on 7 of the 12 factors compared between the two stocks.

How does SOPHiA GENETICS compare to Vir Biotechnology?

SOPHiA GENETICS (NASDAQ:SOPH) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

SOPHiA GENETICS has higher revenue and earnings than Vir Biotechnology. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOPHiA GENETICS$77.27M6.21-$79M-$0.52N/A
Vir Biotechnology$68.56M23.91-$437.99M-$3.13N/A

SOPHiA GENETICS presently has a consensus price target of $7.50, suggesting a potential upside of 31.12%. Vir Biotechnology has a consensus price target of $20.88, suggesting a potential upside of 114.76%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than SOPHiA GENETICS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SOPHiA GENETICS
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Vir Biotechnology
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89

31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

SOPHiA GENETICS has a net margin of -44.48% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -53.31% beat SOPHiA GENETICS's return on equity.

Company Net Margins Return on Equity Return on Assets
SOPHiA GENETICS-44.48% -62.74% -21.85%
Vir Biotechnology -638.88%-53.31%-41.76%

In the previous week, SOPHiA GENETICS had 14 more articles in the media than Vir Biotechnology. MarketBeat recorded 17 mentions for SOPHiA GENETICS and 3 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.81 beat SOPHiA GENETICS's score of 0.02 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SOPHiA GENETICS
6 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Vir Biotechnology
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

SOPHiA GENETICS has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

Summary

Vir Biotechnology beats SOPHiA GENETICS on 10 of the 17 factors compared between the two stocks.

Get SOPHiA GENETICS News Delivered to You Automatically

Sign up to receive the latest news and ratings for SOPH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SOPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SOPH vs. The Competition

Export
MetricSOPHiA GENETICSMEDICAL INFO SYS IndustryMedical SectorNASDAQ Exchange
Market Cap$474.01M$1.81B$7.05B$12.61B
Dividend YieldN/AN/A2.68%8.00%
P/E Ratio-11.0077.2427.1124.26
Price / Sales6.217.33587.92117.88
Price / CashN/A27.3929.2249.36
Price / Book8.295.6210.756.29
Net Income-$79M-$54.76M$3.58B$330.66M
7 Day Performance5.15%-2.15%-2.06%-1.32%
1 Month Performance17.21%5.30%3.32%-0.64%
1 Year Performance65.32%0.86%26.36%19.08%

SOPHiA GENETICS Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SOPH
SOPHiA GENETICS
2.4227 of 5 stars		$5.72
+1.2%		$7.50
+31.1%		+63.9%$474.01M$77.27MN/A520
MAZE
Maze Therapeutics
1.9299 of 5 stars		$32.84
+1.5%		$66.00
+101.0%		+93.9%$1.79B$167.50MN/A121
CMPS
Compass Pathways
2.7875 of 5 stars		$12.99
+1.2%		$24.42
+88.0%		+259.4%$1.73BN/AN/A120
NNNN
Anbio Biotechnology
0.8036 of 5 stars		$11.70
-2.8%		N/AN/A$1.73B$8.65MN/A27
TRLV
Trulieve Cannabis
1.2016 of 5 stars		$8.87
+0.5%		N/AN/A$1.70B$1.17BN/A9,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SOPH) was last updated on 7/14/2026 by MarketBeat.com Staff.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
They told you not to miss this one
The largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...
Thor Metals | Sponsoredtc pixel
Forget SpaceX, this is Elon’s Next Breakthrough
Jeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...
Brownstone Research | Sponsoredtc pixel
When I found Rolls-Royce under $2, most people thought I was crazy
In 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...
Monument Traders Alliance | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel